Galecto (Nasdaq:GLTO) - Cotización, noticias y análisis

Resumen de acción GLTO

Galecto, Inc. es una empresa biotecnológica en fase clínica que desarrolla moléculas para el tratamiento de la fibrosis, el cáncer, la inflamación y otras enfermedades relacionadas.

Acerca de la empresa

GLTO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Tiene menos de 1 año de cash runway

Se prevé que los beneficios disminuyan un promedio de 15.7% al año durante los próximos 3 años

No tiene una capitalización de mercado significativa ($18M)

+ 3 riesgos adicionales

Competidores de Galecto, Inc.

Nascent Biotech

OTCPK:NBIO

US$14.5m

PharmaCyte Biotech

NasdaqCM:PMCB

US$17.8m

NeuroBo Pharmaceuticals

NasdaqCM:NRBO

US$15.4m

BiomX

NYSEAM:PHGE

US$19.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Galecto
Historical stock prices
Current Share Price	US$0.70
52 Week High	US$3.70
52 Week Low	US$0.50
Beta	1.25
1 Month Change	-9.64%
3 Month Change	5.19%
1 Year Change	-59.95%
3 Year Change	-87.68%
5 Year Change	n/a
Change since IPO	-95.30%

Noticias y actualizaciones recientes

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Jan 10

Recent updates

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Oct 19

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Oct 19

Galecto GAAP EPS of -$0.67 beats by $0.02

Jul 29

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Jun 30

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Mar 10

Galecto: Selling At Cash Value

Dec 19

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Nov 18

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Jul 07

Galecto EPS misses by $0.07

May 04

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Mar 23

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Jan 29

Galecto EPS misses by $41.65

Dec 11

Rentabilidad de los accionistas

	GLTO	US Biotechs	Mercado US
7D	3.4%	-0.2%	2.9%
1Y	-60.0%	-1.0%	22.2%

Rentabilidad vs. Industria: GLTO obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 0.7%.

Rentabilidad vs. Mercado: GLTO obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is GLTO's price volatile compared to industry and market?
GLTO volatility
GLTO Average Weekly Movement	10.5%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de GLTO ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GLTO ha disminuido de 16% a 10% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2011	13	Hans Schambye	galecto.com

Galecto, Inc. es una empresa biotecnológica en fase clínica que desarrolla moléculas para el tratamiento de la fibrosis, el cáncer, la inflamación y otras enfermedades relacionadas. El principal producto candidato de la empresa es GB2064, que se encuentra en fase IIa para el tratamiento de la mielofibrosis. También desarrolla GB2064, un inhibidor oral selectivo de molécula pequeña de LOXL2 que está en fase 2a de ensayo clínico para el tratamiento de enfermedades fibróticas, incluidos el cáncer y la mielofibrosis; y GB1211, un inhibidor oral selectivo de galectina-3 que está en fase IIa para el tratamiento del cáncer, así como en fase Ib/IIa para la fibrosis.

Resumen de fundamentos de Galecto, Inc.

¿Cómo se comparan los beneficios e ingresos de Galecto con su capitalización de mercado?
Estadísticas fundamentales de GLTO
Capitalización bursátil	US$19.11m
Beneficios(TTM)	-US$38.35m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.5x

Ratio precio-beneficio (PE)

¿Está GLTO sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GLTO
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$38.35m
Beneficios	-US$38.35m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.41
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GLTO a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GLTO

Recompensas

Análisis de riesgos

Competidores de Galecto, Inc.

OTCPK:NBIO

US$14.5m

NasdaqCM:PMCB

US$17.8m

NasdaqCM:NRBO

US$15.4m

NYSEAM:PHGE

US$19.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Recent updates

New major risk - Financial position

New minor risk - Share price stability

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

Insufficient new directors

Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis

Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial

Galecto Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Financial position

Price target increased by 17% to US$12.00

Here's Why Galecto (NASDAQ:GLTO) Must Use Its Cash Wisely

Price target increased by 18% to US$10.25

Will Galecto (NASDAQ:GLTO) Spend Its Cash Wisely?

Price target decreased to US$8.33

High number of new and inexperienced directors

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022

Galecto, Inc’s Galectin-3 Inhibitor GB1211 to Be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto’s GB1211 to be studied for phase 2 trial in combination with pembrolizumab to treat cancer

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc Announces Results from A Planned Intermediate Assessment of the Ongoing Phase 2A Trial of GB2064, a LOXL2 Inhibitor Product Candidate, for the Treatment of Myelofibrosis

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Price target decreased to US$10.00

Galecto GAAP EPS of -$0.67 beats by $0.02

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Enrolled in Phase 2 Trial of Gb1211 in Combination with Atezolizumab for First-Line Treatment of Nsclc

Price target decreased to US$11.00

High number of new directors

Galecto, Inc. Completes Enrollment in Global Phase 2B GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Is Galecto (NASDAQ:GLTO) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$9.50

Price target decreased to US$11.67

Galecto Publishes Results Showing Safety and Efficacy of the Gb0139 Inhaled Galectin-3 Inhibitor in Hospitalized Covid-19 Patients on Standard of Care

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Galecto: Selling At Cash Value

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

We're Keeping An Eye On Galecto's (NASDAQ:GLTO) Cash Burn Rate

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor Gb1211 in Liver Cirrhosis

Galecto, Inc. Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor Gb2064 in Myelofibrosis (The MYLOX-1 Trial)

Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of GB0139 for Idiopathic Pulmonary Fibrosis

Here's Why We're Watching Galecto's (NASDAQ:GLTO) Cash Burn Situation

Galecto, Inc. Announces Preliminary Topline Results from Galectin-3 Inhibitor GB0139

Galecto EPS misses by $0.07

We Think Galecto (NASDAQ:GLTO) Can Afford To Drive Business Growth

Galecto, Inc. Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

New 90-day low: US$11.99

Do Institutions Own Galecto, Inc. (NASDAQ:GLTO) Shares?

Galecto, Inc. Announces the Appointment of Dr. Anne Prener to Its Board of Directors

Galecto EPS misses by $41.65

Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors

Galecto, Inc. has completed an IPO in the amount of $85.000005 million.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Galecto, Inc.

0.0x